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Depression is a polygenic trait that causes extensive periods of disability. Previous genetic
studies have identified common risk variants which have progressively increased in number
with increasing sample sizes of the respective studies. Here, we conduct a genome-wide
association study in 322,580 UK Biobank participants for three depression-related pheno-
types: broad depression, probable major depressive disorder (MDD), and International
Classification of Diseases (ICD, version 9 or 10)-coded MDD. We identify 17 independent loci
that are significantly associated (P < 5 × 10−8) across the three phenotypes. The direction of
effect of these loci is consistently replicated in an independent sample, with 14 loci likely
representing novel findings. Gene sets are enriched in excitatory neurotransmission,
mechanosensory behaviour, post synapse, neuron spine and dendrite functions. Our findings
suggest that broad depression is the most tractable UK Biobank phenotype for discovering
genes and gene sets that further our understanding of the biological pathways underlying
depression.
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Depression is ranked as the largest contributor to globaldisability affecting 322 million people1. The heritability(h2) of major depressive disorder (MDD) is estimated at
37% from twin studies2, and common single nucleotide poly-
morphisms (SNPs) contribute ~9% to variation in liability3,
providing strong evidence of a genetic contribution to its causa-
tion. Previous genetic association studies have used a number of
depression phenotypes, including self-declared depression4,
depressive symptoms5, clinician diagnosed MDD6 and depression
ascertained via hospital records7. The favouring of greater sample
size over clinical precision has yielded a steady increase over time
in the number of variants for ever more diverse depression-
related phenotypes3,4,6,8. Differing definitions of depression are
rarely available within large studies, however, UK Biobank is a
notable exception.
The UK Biobank cohort has been extensively phenotyped,
allowing us to derive three depression traits: self-reported past
help-seeking for problems with “nerves, anxiety, tension or
depression” (termed “broad depression”), self-reported depressive
symptoms with associated impairment (termed “probable MDD”)
and MDD identified from International Classification of Diseases
(ICD)-9 or ICD-10-coded hospital admission records (termed
“ICD-coded MDD”). The broad depression phenotype is likely to
incorporate a number of personality and psychiatric disorders,
whereas the probable MDD and ICD-coded MDD potentially
offer more robust definitions for depression.
The UK Biobank cohort provides data on over 500,000 indi-
viduals and represents an opportunity to conduct a large genome-
wide association study (GWAS) of depression, followed by
replication of the significant loci in an independent cohort. We
calculated the h2 of the three UK Biobank definitions of
depression and the genetic correlations between them. We also
calculated the genetic correlations between the three depression
phenotypes and other psychiatric disorders and a range of disease
traits. We conducted further analyses to identify genes, regions,
gene sets and tissues associated with each phenotype and used
GTEx9 to identify significant variants that were expression
quantitative trait loci (eQTL). This approach allowed us to
identify replicable loci associated with depression which were
enriched across a number of plausible genes and gene sets
involved in synaptic pathways.
Results
Genome-wide association study of depression. We conducted a
genome-wide association study testing the effect of 7,666,894
variants on three depression phenotypes (broad depression,
probable MDD and ICD-coded MDD) using up to 322,580 UK
Biobank participants. Broad depression was based on self-
reported help-seeking behaviour for mental health difficulties
from either a general practitioner or psychiatrist. Probable MDD
was based on the Smith et al.10 definition of MDD studied pre-
viously in UK Biobank. ICD-coded MDD was based on either a
primary or secondary diagnosis of MDD in hospital admission
records. The study demographics for the case and control groups
within each UK Biobank phenotype are provided in Supple-
mentary Table 1. A total of 17 independent variants were
genome-wide significant (P < 5 × 10−8) across the three depres-
sion phenotypes analysed (Table 1), of which 14 were associated
with broad depression, two were associated with probable MDD
and one was associated with ICD-coded MDD. The effect sizes,
standard errors and P-values for the associated variants across the
three phenotypes are provided in Supplementary Data 1, with
odds ratios calculated using a logistic regression model in Plink
v1.90b411. Replication of the 17 associated variants was sought
using the association study of depression performed using
research participants from the personal genetics company
23andMe, Inc., conducted by Hyde et al4. There were 16 variants
that had an effect in the same direction as the 23andMe analysis,
with seven variants shown to be significant (P < 0.0029) in the
23andMe cohort after applying a Bonferroni correction (Table 1).
All 17 variants remained significant (P < 5 × 10−8) in the meta-
analysis. Fourteen out of the 17 significant variants identified
within our analysis of UK Biobank were novel, i.e. not reported
within ±500 Kb of a significant variant (P < 5 × 10−8) reported by
either Hyde et al.4, Okbay et al.5, or the Converge Consortium7.
The three variants (rs6699744, rs6424532 and rs1021363) that
were unlikely to be novel were close to variants identified by Hyde
et al4.
Manhattan plots of all the variants analysed in UK Biobank are
provided in Figs. 1, 2 and 3 for broad depression, probable MDD
and ICD-coded MDD, respectively. Q–Q plots of the observed
P-values on those expected are provided in Supplementary
Figs. 1, 2, and 3 for broad depression, probable MDD and
ICD-coded MDD, respectively. There were 3,690 variants with
P < 10−6 for an association with broad depression (Supplemen-
tary Data 2), 189 for probable MDD (Supplementary Data 3), and
107 for ICD-coded MDD (Supplementary Data 4). None of the
phenotypes examined provided evidence of inflation of the test
statistics due to population stratification, with any inflation due to
polygenic signal (intercepts, standard errors and genomic
inflation factors for each phenotype, calculated using Linkage
Disequilibrium Score Regression (LDSR), are provided in
Supplementary Table 2). Regional visualisation plots of
rs3807865, rs1021363 and rs10501696 are provided in Supple-
mentary Figs. 4, 5, and 6, respectively.
Heritability of depression. The SNP-based h2 estimates on the
liability scale for the whole sample using LDSR were 10.2%
( ± 0.4%), 4.7% ( ± 0.6%) and 10.0% ( ± 1.2%) for broad
depression, probable MDD and ICD-coded MDD, respectively.
We estimated the SNP-based h2 on the liability scale for each
depression phenotype in UK Biobank using GCTA-GREML12
within each recruitment centre and also by geographical region
(Supplementary Tables 3, 4 and Fig. 4 (broad depression)). The
SNP-based h2 estimates for each region ranged from 8.4% to
17.8% for broad depression, 0% to 27.5% for probable MDD and
from 0% to 25.4% for ICD-coded MDD. There was no
evidence of heterogeneity between geographical regions for
broad depression (I-squared= 0%, P= 0.58), probable MDD
(I-squared= 33.1%, P= 0.18) or ICD-coded MDD
(I-squared= 0%, P= 0.69).
Genetic correlations with depression. Strong genetic correla-
tions (rg) were found between each of the three UK Biobank
depression phenotypes (0.85 ( ± 0.05) ≤ rg ≤ 0.87 ( ± 0.05),
P ≤ 4.21 × 10−59) using LDSR13 (Supplementary Table 5). There
were also significant differences (P < 0.003) between each of the
three phenotypes when assessing whether rg= 1.
LD Hub14 was then used to calculate the genetic correlations
between each depression phenotype and 235 other traits
(Supplementary Data 5). After applying a false discovery rate
correction there were 42, 31 and 35 significant correlations with
other traits (PFDR < 0.05) for broad depression, probable MDD
and ICD-coded MDD, respectively. Significantly genetic correla-
tions were observed between the UK Biobank depression-related
phenotypes and the results of an analysis of clinically defined
MDD6 (broad depression (rg= 0.79 ± 0.07, PFDR= 3.79 × 10−25),
probable MDD (rg= 0.64 ± 0.12, PFDR= 7.95 × 10−6) and ICD-
coded MDD (rg= 0.63 ± 0.10, PFDR= 1.86 × 10−8)). LD Hub14
also identified significant genetic correlations between the three
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depression phenotypes and schizophrenia15 (0.29 ( ± 0.04) ≤ rg ≤
0.30 ( ± 0.05), PFDR ≤ 4.60 × 10−9). Broad depression and prob-
able MDD were significantly genetically correlated with bipolar
disorder16 (rg= 0.33 ( ± 0.07), PFDR ≤ 5.44 × 10−5) and broad
depression was genetically correlated with attention deficit
hyperactivity disorder (ADHD)17 (rg= 0.36 ( ± 0.11), PFDR=
0.01). No significant genetic correlations (PFDR > 0.33) were found
between autism spectrum disorder and the three depression-
related phenotypes.
Gene and region-based analyses. We used the MAGMA18
package to identify genes with a significant effect (P < 2.77 × 10−6)
on each phenotype. There were 78 genes significantly associated
with broad depression (Supplementary Data 6), two genes that
were associated with probable MDD (Supplementary Data 7) and
one gene that was associated with ICD-coded MDD (Supple-
mentary Data 8).
We also used MAGMA to identify genomic regions, defined by
recombination hotspots, with a statistically significant effect (P <
6.02 × 10−6) on each phenotype. There were 59 significant
regions identified for broad depression, four regions identified
for probable MDD, and four regions for ICD-coded MDD.
Further details regarding these regions are provided in Supple-
mentary Data 9, 10, and 11 for broad depression, probable MDD
and ICD-coded MDD, respectively.
Manhattan plots of the gene and regions analysed are provided
in Supplementary Figs. 7, 8, and 9 for broad depression, probable
MDD, and ICD-coded MDD, respectively.
Gene-set pathway analysis. We conducted gene-set enrichment
analysis19,20 and identified five significant pathways for broad
depression after applying correction for multiple testing;
GO_EXCITATORY_SYNAPSE (beta= 0.346 ± 0.069, Pcorrected =
0.004), GO_MECHANOSENSORY_BEHAVIOR (beta= 1.390 ±
0.290, Pcorrected = 0.009), GO_POSTSYNAPSE (beta= 0.241 ±
0.050, Pcorrected = 0.009), GO_NEURON_SPINE (beta= 0.376 ±
0.085, Pcorrected= 0.035) and GO_DENDRITE (beta= 0.195 ±
0.045, Pcorrected = 0.041) (Table 2). The genes within each of these
significant pathways is provided in Supplementary Data 12 and
the gene overlap between each pathway are provided in Supple-
mentary Table 6. No pathways were associated (P > 0.05) with
probable MDD or ICD-coded MDD after multiple testing
correction.
Tissue enrichment analysis. The summary statistics from the
three phenotypes were examined for enrichment in 209 different
tissues using DEPICT21. None of the tissues showed significant
enrichment across the three depression-related phenotypes, after
applying the default false discovery rate correction (Supplemen-
tary Data 13). However, within broad depression the tissues that
showed greatest enrichment were those involved in the brain and
nervous system.
eQTL identification. Of the 17 variants associated with depres-
sion, 7 were identified as eQTLs (Supplementary Data 14); of
these, 4 variants were found to be eQTL for brain expressed
genes. rs6699744 is associated with the expression of RPL31P12 in
Table 1 Independent variants with a genome-wide significant (P < 5 × 10−8) association with broad depression, probable major
depressive disorder (MDD) or International Classification of Diseases (ICD)-coded MDD in UK Biobank
UK Biobank 23andMe Meta-analysis
Phenotype Chr Marker
name
Position A1/
A2
Freq Info Beta (St.
err)
Gene+ /−
10 kb
P-value Beta (St.
err.)
P-value Beta (St.
err.)
P-value Direction
Broad
depression
1 rs10127497 67050144 T/A 0.138 1.00 0.0097
(0.0017)
SGIP1 1.29 ×
10−8
0.0098
(0.0086)
0.257 0.0097
(0.0017)
6.63 ×
10−9
++
1 rs6699744 72825144 T/A 0.612 1.00 0.0089
(0.0012)
— 1.64 ×
10−13
0.0328
(0.0064)
2.68 ×
10−7
0.0098
(0.0012)
2.29 ×
10−16
++
1 rs6424532 73664022 A/G 0.486 1.00 0.0065
(0.0012)
— 3.91 ×
10−8
0.0233
(0.006)
1.14 ×
10−4
0.0071
(0.0012)
8.71 ×
10−10
++
1 rs7548151 177026983 A/G 0.084 1.00 0.0125
(0.0021)
ASTN1 3.87 ×
10−9
0.006
(0.0104)
0.560 0.0122
(0.0021)
3.93 ×
10−9
++
5 rs40465 103981726 G/T 0.332 1.00 0.0078
(0.0013)
RP11-6N13.1 4.45 ×
10−10
0.0193
(0.0064)
2.63 ×
10−3
0.0082
(0.0012)
2.10 ×
10−11
++
6 rs3132685 29945949 A/G 0.130 1.00 −0.0131
(0.0018)
— 2.47 ×
10−13
−0.0249
(0.0099)
0.011 −0.0134
(0.0018)
1.97 ×
10−14
−−
6 rs112348907 73587953 G/A 0.296 1.00 0.0073
(0.0013)
— 1.52 ×
10−8
−0.0004
(0.0067)
0.950 0.0071
(0.0013)
2.96 ×
10−8
+−
7 rs3807865 12250402 A/G 0.412 1.00 0.0082
(0.0012)
TMEM106B 7.28 ×
10−12
0.019
(0.0061)
2.00 ×
10−3
0.0086
(0.0012)
2.55 ×
10−13
++
7 rs2402273 117600424 C/T 0.409 1.00 0.0072
(0.0012)
— 1.95 ×
10−9
0.0093
(0.0061)
0.130 0.0073
(0.0012)
6.37 ×
10−10
++
9 rs263575 17033840 A/G 0.460 1.00 −0.0066
(0.0012)
— 2.31 ×
10−8
−0.0157
(0.0061)
9.45 ×
10−3
−0.0069
(0.0012)
2.23 ×
10−9
−−
10 rs1021363 106610839 G/A 0.642 1.00 −0.007
(0.0012)
SORCS3 1.04 ×
10−8
−0.031
(0.0063)
9.34 ×
10−7
−0.0079
(0.0012)
5.54 ×
10−11
−−
11 rs10501696 88748162 G/A 0.499 0.99 −0.0079
(0.0012)
GRM5 6.73 ×
10−11
−0.0251
(0.0066)
1.49 ×
10−4
−0.0084
(0.0012)
1.24 ×
10−12
−−
13 rs9530139 31847324 T/C 0.195 1.00 −0.0089
(0.0015)
B3GLCT 2.63 ×
10−9
−0.0075
(0.0078)
0.338 −0.0088
(0.0015)
1.66 ×
10−9
−−
15 rs28541419 88945878 G/C 0.231 1.00 −0.0078
(0.0014)
— 2.78 ×
10−8
−0.0029
(0.0073)
0.688 −0.0076
(0.0014)
3.18 ×
10−8
−−
Probable
MDD
2 rs10929355 15398964 G/T 0.456 1.00 −0.0075
(0.0013)
NBAS 5.84 ×
10−9
−0.0078
(0.0061)
0.199 −0.0075
(0.0013)
2.50 ×
10−9
−−
7 rs5011432 12268668 C/A 0.412 1.00 0.0073
(0.0013)
TMEM106B 2.23 ×
10−8
0.022
(0.0061)
3.15 ×
10−4
0.008
(0.0013)
4.85 ×
10−10
++
ICD-coded
MDD
7 rs1554505 1983929 A/G 0.752 1.00 0.004
(0.0007)
MAD1L1 2.74 ×
10−9
0.017
(0.007)
0.015 0.0042
(0.0007)
7.58 ×
10−10
++
Variants were examined within the 23andMe association analysis of depression4 to obtain their reported P-values and determine whether their effect was in the same direction as UK Biobank
The allele frequency (Freq) is for the A1 allele within UK Biobank, with the effect size (Beta) and standard error (St. err.) reported for the A1 allele within UK Biobank, 23andMe and the meta-analysis. The
chromosome (Chr) and basepair position is given with regards to the GRCh37 assembly. Imputation accuracy (Info) score of UK Biobank was calculated based on the sample analysed
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the cerebellum, and rs9530139 is associated with expression of
B3GALTL in the cortex. rs40465 and rs68141011 are broad
eQTLs affecting the expression of a number of zinc finger protein
encoding genes across various brain tissues, including ZNF391,
ZNF204P, ZNF192P1, ZSCAN31 and ZSCAN23. None of these
brain expressed genes overlapped with the genes within the five
significant gene-pathways highlighted previously.
Discussion
This study describes a large analysis of depression-related phe-
notypes using a single population-based cohort. Up to 322,580
individuals from the UK Biobank cohort were used to test the
effect of 7,666,894 genetic variants on three depression pheno-
types. A total of 17 independent genome-wide significant (P < 5 ×
10−8) variants were identified across the three phenotypes.
Replication was sought for these 17 variants within the 23andMe
cohort4. We found that 16 of these variants had an effect in the
same direction as UK Biobank, with seven of the variants in the
replication cohort being significant after correction for multiple
testing (P < 0.0029). The broadest definition of the phenotype,
broad depression, provided the greatest number of individuals for
analysis and also the largest number of significant hits (14
independent variants). The probable MDD phenotype was
obtained using the approach of Smith, et al.10, using responses to
touchscreen items that were only administered in the last two
years of UK Biobank recruitment. Thus, the probable MDD
phenotype was only available for approximately one-third of the
sample, and yielded two independent genome-wide significant
variants. The strictest phenotype, ICD-coded MDD (using linked
hospital admission records for a primary or secondary diagnosis
of ICD 9/10 MDD), had one independent significant variant.
Strong positive genetic correlations were found between the
three UK Biobank phenotypes and a mega-analysis of MDD,
based on an anchor set of clinically defined cases. Interestingly,
the highest genetic correlation with the clinically defined MDD
phenotype was for the broad depression phenotype. The broad
depression phenotype was genetically correlated with the greatest
number of other traits, including schizophrenia, bipolar disorder
and ADHD, with these correlations in general alignment with
those reported by Major Depressive Disorder Working Group of
the Psychiatric Genomics Consortium., et al.3. The very high
genetic correlations between the three phenotypes for depression
within UK Biobank is not surprising as there is overlap between
individuals classified as cases. However, we also showed sig-
nificant differences between the underlying genetic architectures
of the three phenotypes, and these differences may be informative
for defining depression-related phenotypes.
Where each phenotype differed most, was in its tractability for
discovering specific genetic loci with UK Biobank. Despite the
majority of the cross-phenotype effect sizes being in the same
direction (32 out of 34), only half demonstrated a nominally sig-
nificant association (P < 0.05). This variability in the variants
underlying each phenotype potentially suggests that depression
phenotypes may differ in their tractability for genetic studies. The
number of cases for probable MDD (n= 30,603) and ICD-coded
MDD (n= 8,276) was considerably lower than for broad depression
(n= 113,769). The power to detect significant effects for probable
MDD and ICD-coded MDD could be limited, because at those
sample sizes, no variants have yet achieved replicable associations
for depression. Whilst false positive associations could also explain
non-overlap between the findings for the three UK Biobank
depression phenotypes, replication of our findings in an indepen-
dent cohort suggests that this is not the case.
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Fig. 1 Manhattan plot of the observed –log10 P-values of each variant for an association with broad depression (n= 322,580) in the UK Biobank cohort.
Variants are positioned according to the GRCh37 assembly
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There were a number of genes identified as associated with
depression, as well as genes that overlapped with the associated
variants. For brevity of this discussion, these genes and their
putative effects and biological pathways are covered in greater
depth in Supplementary Note 1. The genes that are potentially of
interest for the study of depression include the Neural Growth
Regulator 1 (NEGR1), the glutamate metabotropic receptor 5
(GRM5), the glutamate ionotropic receptor kainate type subunit 3
(GRIK3) and the transmembrane protein 106B (TMEM106B)
protein coding genes.
Five gene sets were significantly enriched in broad depression.
Of these, four were associated with cellular components (where
the genes are active), and one was associated with a biological
process. The cellular components were all associated with parts of
the nervous system (excitatory synapse, neuron spine, post-
synapse and dendrite) and demonstrates that genes that are active
in these components could be attributing to depression. However,
there was considerable overlap between the genes that were
involved in the cellular components. Excitatory synapses are the
site of release for excitatory neurotransmitters and have been
previously associated with depression- related phenotypes22,23,
with the most common excitatory neurotransmitter, glutamate,
also demonstrating associations with depression24,25. The detec-
tion of this pathway, using a genome-wide association analysis
approach, allows the specific genes driving this association to be
identified, with sortilin-related VPS10 domain containing recep-
tor 3 (SORCS3), GRM5, dopamine receptor D2 (DRD2) and
calcium binding protein 1 (CABP1) the most significant genes for
broad depression in this pathway. Neuron spines (or dendritic
spines) are extensions from dendrites that act as a primary site for
excitatory transmission in the brain. Imbalances of excitation and
inhibition have been previously associated with other mental
disorders such as schizophrenia, Tourette’s syndrome and autism
spectrum disorder26. These results indicate that the role of exci-
tatory synapses in the pathology of depression should be further
investigated.
Mechanosensory behaviour refers to behaviour that is
prompted from a mechanical stimulus (e.g. physical contact with
an object). This indicates that depressive individuals may have a
differing behavioural response to mechanosensory stimuli, with
higher pain sensitivity and lower pain pressure thresholds found
in depression cases27. The identification of the genes involved in
each of the pathways reported may ultimately be informative of
the underlying biological processes for each phenotype.
We derived three definitions of depression in the UK Biobank
cohort. The broad depression phenotype provided the greatest
number of cases and was based on self-reported help-seeking
behaviour via a general practitioner or psychiatrist, and therefore
is likely to also capture other personality disorders. To examine
potential overlap with generalised anxiety disorder we used
LDSR13 to calculated genetic correlations with our three
depression-related phenotypes and anxiety factors score from
Otowa, et al.28. There was no clear evidence for additional
enrichment for anxiety disorder in the broad depression pheno-
type (rg= 0.052 ± 0.11) compared to probable MDD (rg= 0.060
± 0.17) or ICD-coded MDD (rg= 0.047 ± 0.17). The probable
MDD supplemented help-seeking behaviour with additional
information relating to low mood and/or anhedonia over a two-
week period and the ICD-coded MDD phenotype was based on a
hospital-treated and healthcare-professional-coded diagnosis of
MDD. The ICD-coded MDD phenotype provided substantially
fewer cases, many of which were secondary, or potentially inci-
dental, to medical diagnoses.
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Fig. 2 Manhattan plot of the observed –log10 P-values of each variant for an association with probable major depressive disorder (n= 174,519) in the UK
Biobank cohort. Variants are positioned according to the GRCh37 assembly
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Although useful for genetic studies, each depression phenotype
has limitations. None are based on a formal structured diagnostic
assessment (such as the Structured Clinical Interview for DSM
Axis 1 Disorders interview), and both the broad depression and
probable MDD phenotypes are based on self-reported informa-
tion, which can be subject to recall biases. Broad depression is
also likely to be endorsed by a wider range of individuals than
traditional depression definitions, including those with inter-
nalising disorders other than depression and those with depres-
sive symptoms that would not meet diagnostic criteria for MDD.
The ICD-coded MDD phenotype is based on hospital admission
records, which can sometimes be incomplete as not all partici-
pants would have a hospital admission leading to a diagnosis of
MDD. This phenotype provided just one genome-wide significant
variant which may represent the extent of the detectable signal
available for a clinically MDD diagnosis in a population of the
size studied.
However, in alignment with Hyde et al.4, we found that self-
reported measures of depression were highly genetically corre-
lated with those obtained from the clinically-diagnosed depres-
sion phenotype6. Therefore, the analysis of large cohorts with
self-reported depression appears to offer greater power for
detecting genetic effects than smaller studies with a more robustly
defined clinical phenotype. Depression is, however, a hetero-
geneous condition29,30 and to gain greater insight into its sub-
types, larger studies are likely to be necessary to improve
diagnosis, treatment and patient outcomes. This approach might
only be possible with relatively easy-to-recruit, large, population-
based self-declared cohorts, supplemented where feasible with
additional clinical and biological data.
In a large genome-wide association study of three depression-
related phenotypes in UK Biobank, we identified 17 risk variants.
In a replication sample, consistency of direction of effect was seen
with seven variants formally replicated. Further analysis of our
results identified genetic correlations with a number of other
psychiatric disorders and implicating perturbations of excitatory
neurotransmission in depression. Our results suggest that a broad
depression phenotype, which potentially overlaps with other
personality and psychiatric traits, may provide a more tractable
target for future genetic studies, allowing the inclusion of many
more samples.
Methods
Study population. The UK Biobank cohort is a population-based cohort consisting
of 501,726 individuals recruited at 23 centres across the United Kingdom. Geno-
typic data was available for 488,380 individuals and was imputed with IMPUTE4
using the HRC reference panel31 to identify ~39M variants for 487,409 indivi-
duals32. We excluded 79,990 individuals that were outliers based on heterozygosity,
had a variant call rate <98%, or were not recorded as “white British”. We excluded
a further 131,790 related individuals based on a shared relatedness of up to the
third degree using kinship coefficients (>0.044) calculated using the KING tool-
set33; we then subsequently added back in one member of each group of related
individuals by creating a genomic relationship matrix and selected individuals with
a genetic relatedness less than 0.025 with any other participant (n= 55,745). We
removed variants with a call rate < 98%, a minor allele frequency <0.01, deviation
from Hardy–Weinberg equilibrium (P < 10−6) or an imputation accuracy (Info)
score < 0.1, leaving a total of 7,666,894 variants for 331,374 individuals.
Extensive phenotypic data were collected for UK Biobank participants using
health records, biological sampling, physical measures and touchscreen tests and
questionnaires. We used three definitions of depression in the UK Biobank sample,
which are explained in greater depth in Supplementary Note 2 and are described
below. For the three UK Biobank depression phenotypes, we excluded participants
who were identified with bipolar disorder, schizophrenia or personality disorder
using self-declared data, touchscreen responses (per Smith, et al.10) or ICD codes
from hospital admission records; and participants who reported having a
prescription for an antipsychotic medication during a verbal interview. Further
exclusions were applied to all control individuals if they had a diagnosis of a
depressive mood disorder from hospital admission records, had reported having a
–
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Fig. 3 Manhattan plot of the observed –log10 P-values of each variant for an association with International Classification of Diseases-coded major
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prescription for antidepressants or had self-reported depression (see
Supplementary Note 2 for full phenotype criteria).
This research has been conducted using the UK Biobank Resource—application
number 4844. The UK Biobank study was conducted under generic approval from
the NHS National Research Ethics Service (approval letter dated 17th June 2011,
Ref 11/NW/0382). All participants gave full informed written consent.
Broad depression phenotype. The broadest phenotype (broad depression) was
defined using self-reported help-seeking behaviour for mental health difficulties.
Case and control status was determined by the touchscreen response to either of
two questions: “Have you ever seen a general practitioner (GP) for nerves, anxiety,
tension or depression?” (UK Biobank field: 2090) or “Have you ever seen a psy-
chiatrist for nerves, anxiety, tension or depression?” (UK Biobank field 2010).
Caseness for broad depression was determined by answering “Yes” to either
question at either the initial assessment visit, at any repeat assessment visit, or if
there was a primary or secondary diagnosis of a depressive mood disorder from
linked hospital admission records (UK Biobank fields: 41202 and 41204; ICD
codes: F32—Single Episode Depression, F33—Recurrent Depression, F34—Per-
sistent mood disorders, F38—Other mood disorders and F39—Unspecified mood
disorders). The remaining respondents were classed as controls if they provided
“No” responses to both questions during all assessments that they participated in.
This provided a total of 113,769 cases and 208,811 controls (ntotal= 322,580,
prevalence= 35.27%) for the broad depression phenotype. Individuals classed as
cases for the broad depression phenotype potentially included individuals seeking
treatment for personality disorders.
Probable MDD phenotype. The second depression phenotype (probable MDD)
was derived from touchscreen responses to questions about the presence and
duration of low mood and anhedonia, following the definitions from Smith et al.10,
whereby the participant had indicated that they were “depressed/down for a whole
week (UK Biobank field: 4598); plus at least 2 weeks duration (UK Biobank field:
4609); plus ever seen a GP or psychiatrist for nerves, anxiety or depression” (UK
Biobank fields: 2090 and 2010), or “ever anhedonia for a whole week (UK Biobank
field: 4631); plus at least 2 weeks duration (UK Biobank field: 5375); plus ever seen
a GP or psychiatrist for nerves, anxiety, or depression” (UK Biobank fields: 2090
and 2010). Cases for the probable MDD definition were supplemented by diag-
noses of depressive mood disorder from linked hospital admission records (UK
Biobank fields: 41202 and 41204) as per the broad depression phenotype. There
were a total of 30,603 cases and 143,916 controls (ntotal= 174,519, prevalence=
17.54%) for the probable MDD phenotype.
There were 66,176 individuals that were classed as controls for probable MDD, who
were classed as cases for broad depression. This was due to stricter conditions for
classification as a case for probable MDD compared to the broad depression
phenotype, and potentially removes individuals seeking treatment for personality
disorders.
ICD-coded MDD phenotype. The ICD-coded MDD phenotype was derived from
linked hospital admission records (UK Biobank fields: 41202 and 41204). Partici-
pants were classified as cases if they had either an ICD-9/10 primary or secondary
diagnosis for a depressive unipolar mood disorder (ICD codes: F32—Single Epi-
sode Depression, F33—Recurrent Depression, F34—Persistent mood disorders,
F38—Other mood disorders and F39—Unspecified mood disorders). ICD-coded
MDD controls were participants who had linked hospital records, but who did not
have any diagnosis of a mood disorder and were not probable MDD cases. There
were 8,276 cases and 209,308 controls (ntotal= 217,584, prevalence= 3.80%) for
the ICD-coded MDD phenotype.
There were no individuals classed as a case for ICD-coded MDD who were
classed as a control for either the broad depression or probable MDD phenotypes.
There were no individuals classed as controls in ICD-coded MDD who were
classed as a case for probable MDD. However, there were 53,491 control
individuals for ICD-coded MDD who were classed as a control for broad
depression, which reflects the potentially looser definition stipulated under the
broad depression phenotype. Of the 8,276 individuals classed as a case using the
ICD-coded MDD definition, 7,471 (90.3%) also reported seeing either a GP or
psychiatrist for nerves, anxiety, or depression (UK Biobank fields: 2090 and 2010),
or had been depressed/down or suffered from anhedonia for a whole week (UK
Biobank field: 4598).
A cross tabulation of case and control status between each pair of phenotypes is
provided in Supplementary Table 7.
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Fig. 4 Forest plot of the estimated SNP-based heritability of broad depression by recruitment centre and region. Heritabilities are provided where there was
power of at least 30% to detect a heritability >0 with a trait heritability of 9%, a type I error of 0.05, a trait prevalence of 0.3527 and a variance of the SNP-
derived genetic relationships of 2 × 10−5
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Association analysis. We performed a linear association test to assess the effect of
each variant using BGENIE v1.132:
y ¼ Xβþ ε1
y^ ¼ Xβ
ðy  y^Þ ¼ Gbþ ε2
where y was the vector of binary observations for each phenotype (controls
coded as 0 and cases coded as 1). β was the matrix of fixed effects, including sex,
age, genotyping array, and 8 principal components. X was the corresponding
incidence matrices. ðy  y^Þ was a vector of phenotypes residualized on the fixed
effect predictors, G was a vector of expected genotype counts of the effect allele
(dosages), b was the effect of the genotype on residualized phenotypes, and ε1 and
ε2 were vectors of normally distributed errors.
Genome-wide statistical significance was determined by the conventional
threshold of P < 5 × 10−8. To determine significant variants that were independent,
the clump command in Plink 1.90b411 was applied using --clump-p1 1e-4 --clump-
p2 1e-4 --clump-r2 0.1 --clump-kb 3000, mirroring the approach of Major
Depressive Disorder Working Group of the Psychiatric Genomics Consortium.,
et al.3. Therefore, variants that were within 3Mb of each other and shared a linkage
disequilibrium greater than 0.1 were clumped together, and only the most
significant variant was reported.
Due to the complexity of major histocompatibility complex (MHC) region, an
approach similar to that of The Schizophrenia Psychiatric Genome-Wide
Association Study Consortium34 was taken, and only the most significant variant
across that region was reported. To obtain odds ratios for those variants associated
with depression, a logistic regression was conducted in Plink 1.90b411 using the
same covariates as the linear model above. Regional visualisation plots were
produced using LocusZoom35. Linkage Disequilibrium Score regression (LDSR)13
was used to determine whether there was elevation of the polygenic signal due to
population stratification, by examining the intercept for evidence of significant
deviation ( ± 1.96 standard error) from 1. The genomic inflation factor (λGC) was
also reported for each phenotype.
Replication cohort and meta-analysis. We sought to replicate those variants
within UK Biobank that were identified as significantly associated (P < 5 × 10−8)
with depression. To conduct the replication, we used the associated analysis results
from the discovery sample from the 23andMe cohort4 (n= 307,354, cases= 75,607
and controls= 231,747). We firstly examined if the effect of the A1 allele was in the
same direction across both UK Biobank and 23andMe. Secondly, we determined
whether the variant within 23andMe was significant for the 17 variants (α= 0.05 /
17; P < 0.0029). Additionally, we used Metal36 to conduct an inverse variance-
weighted meta-analysis of these 17 significant variants in UK Biobank and
23andMe.
Heritability of depression. We used GCTA-GREML12 to estimate the SNP-based
h2 for each depression phenotype within each recruitment centre and each region.
The specified population prevalence was matched to that observed across the whole
cohort for each phenotype to allow transformation from the observed to the
underlying liability scale. The recruitment centres within each region is provided in
Supplementary Table 4. LDSR13 was used to provide a whole sample SNP-based
estimate of the h2 on liability scale of the phenotypes using the whole-genome
summary statistics obtained by the association analyses. The summary statistics for
each phenotype were filtered using the default file, w_hm3.snplist, with the default
LD Scores computed using 1000 Genomes European data (eur_w_ld_chr) used as a
reference.
Genetic correlations with depression. To calculate the genetic correlations
between the three depression-related phenotypes in UK Biobank LDSR13 was used.
We also tested that hypothesis that the phenotypes were perfectly correlated with
one another (rg= 1):
P  value ¼ 2 ´ pnorm abs 1 rg
standard error
  
Genetic correlations were also calculated between each of the three phenotypes
and 235 other behavioural and disease related traits using LD Hub14. P-values were
false discovery rate (FDR) adjusted using the Benjamini and Hochberg37 approach.
Gene- and region-based analyses. Two downstream analyses of the results were
conducted using MAGMA18 (Multi-marker Analysis of GenoMic Annotation) by
applying a multiple regression model, which incorporates linkage disequilibrium
between markers and accounts for multi-marker effects, to the results of our
association analyses. Estimates of the linkage disequilibrium between markers were
obtained from the European populations sequenced as part of the 1,000 Genomes
Project (phase 1, release 3)38. In the first downstream analysis, a gene-based
analysis was performed for each phenotype using the results from our GWAS. The
NCBI 37.3 build was used to determine the genetic variants that were ascribed to
each gene. A total of 18,033 genes were assessed for an association with each
depression phenotype with Bonferroni correction used to determine significance
(α= 0.05 / 18,033; P < 2.77 × 10−6).
In the second downstream analysis, a region-based analysis was performed for
each phenotype. To determine the regions, haplotype blocks identified by
recombination hotspots were used as described by Shirali, et al.39 and implemented
in an analysis of MDD by Zeng, et al.40 for detecting causal regions. Block
boundaries were defined by hotspots of at least 30 cM per Mb based on a European
subset of the 1,000 genome project recombination rates. This resulted in a total of
8,308 regions being analysed using the European panel of the 1,000 Genomes data
(phase 1, release 3) as a reference panel to account for linkage disequilibrium. A
genome-wide significance threshold for region-based associations was calculated
using the Bonferroni correction method (α= 0.05 / 8,308; P < 6.02 × 10−6).
Gene-set pathway analysis. We used the results obtained from our gene-based
analysis to conduct a further gene-set pathway analysis to test for gene enrichment
within 5,917 biological classes using MAGMA18. The gene-set pathways were
obtained from the gene-annotation files provided by the Gene Ontology (GO)
Consortium (http://geneontology.org/)19, which are derived from the Molecular
Signatures Database (MSigDB) v5.220. To correct for multiple testing, the default of
10,000 permutations was applied. The estimate of the effect size (beta) reflects the
difference in association between genes in the gene set and genes outside the gene
set from fitting a regression model to the data.
Tissue enrichment analysis. The DEPICT package21 was used to investigate
whether specific tissues were enriched using the genome-wide association study
results obtained for each phenotype. The recommended P-value threshold of <10−5
was applied to the variants used to assess enrichment. DEPICT incorporates data
from 37,427 human gene expression microarrays to determine whether genes in
associated loci for each phenotype were significantly expressed in any of 209 tissue/
cell type annotations.
eQTL identification. The online GTEx portal (https://www.gtexportal.org/home/)
was used to determine whether any of the genome-wide significant variants for
each phenotype were eQTL9.
Code availability. All code used to conduct the research detailed in this manu-
script is available on request from the corresponding author.
Data availability. The summary statistics relating to each of the three depression
phenotypes assessed in this study are available on the Edinburgh DataShare
website, via the following link: https://doi.org/10.7488/ds/2314
Table 2 Pathways with a significant effect (Pcorrected < 0.05) on broad depression following multiple testing correction identified
through gene-set enrichment analysis
Phenotype Pathway Number of genes Beta (St. Err.) P-value PCorrected
Broad depression GO_EXCITATORY_SYNAPSE 182 0.346 (0.069) 2.38 × 10−7 0.004
GO_MECHANOSENSORY_BEHAVIOR 11 1.390 (0.290) 7.99 × 10−7 0.009
GO_POSTSYNAPSE 352 0.241 (0.050) 8.26 × 10−7 0.009
GO_NEURON_SPINE 114 0.376 (0.085) 4.89 × 10−6 0.035
GO_DENDRITE 423 0.195 (0.045) 6.06 × 10−6 0.041
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The raw genetic and phenotypic data that support the findings of this study are
available from UK Biobank but restrictions apply to the availability of these data,
which were used under license for the current study, and so are not publicly
available. Data are, however, available from the authors upon reasonable request
and with permission of UK Biobank (http://www.ukbiobank.ac.uk/).
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